We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Roche Holdings Ltd AG (QX) | USOTC:RHHBY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.23 | 0.77% | 30.25 | 30.15 | 30.26 | 30.28 | 30.07 | 30.10 | 2,908,982 | 22:20:00 |
From Apr 2019 to Apr 2024
By Michael Dabaie
Roche Holding AG's (RO.EB, ROG.EB) Genentech said data was positive from the Phase III IMpower110 study evaluating Tecentriq in advanced non-squamous and squamous non-small cell lung cancer.
Genentech said the study looked at Tecentriq as a monotherapy in advanced non-squamous and squamous non-small cell lung cancer without ALK or EGFR mutations.
The study showed Tecentriq monotherapy helped people with advanced non-small cell lung cancer with high PD-L1 expression live longer compared with chemotherapy alone, Genentech said.
The company said it will share the data with health authorities globally, including the U.S. Food and Drug Administration and European Medicines Agency.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
September 27, 2019 11:05 ET (15:05 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Roche (QX) Chart |
1 Month Roche (QX) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
